Shaosen Zhang,Yanrong Shen,Lingxuan Zhu et al.
Shaosen Zhang et al.
Esophageal cancer (EC), encompassing primarily esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), continues to pose a significant global health burden, which is largely due to delayed diagnosis and limited therap...
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial) [0.03%]
HDAC抑制剂涂地辛加小剂量卡培他滨联合内分泌治疗CDK4/6抑制剂治疗后进展的HR阳性HER2阴性晚期乳腺癌患者的临床疗效及探索性循环肿瘤细胞和ctDNA生物标志物分析：一项多中心II期研究（SYSUCC-020试验）
Huai-Liang Wu,Wen Xia,Zhengyang Xu et al.
Huai-Liang Wu et al.
Treatment options for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that progresses after CDK4/6 inhibitor (CDK4/6i) continue to evolve, and no single reg...
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy [0.03%]
内质网应激与疾病发病机制及治疗的关系
Siyu Wei,Nan Zhang,Hao Zhang et al.
Siyu Wei et al.
Endoplasmic reticulum (ER) stress is a key cellular mechanism that is important in the development of many diseases, including cancer. Since the discovery of the unfolded protein response (UPR), research has greatly improved our understandi...
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer [0.03%]
STRATEGY-1：不可切除的RAS/BRAF野生型转移性结直肠癌患者的多队列、随机、开放标签的GERCOR-PRODIGE-39Ⅲ期临床试验
Benoist Chibaudel,Louis-Marie Dourthe,Thierry André et al.
Benoist Chibaudel et al.
Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize ...
Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth [0.03%]
生物工程来源的诱导多能干细胞衍生的人巨噬细胞通过提高血管紧张素转换酶（ACE）表达来抑制实体肿瘤生长
Tomohiro Shibata,Shabir Bhat,DuoYao Cao et al.
Tomohiro Shibata et al.
The potential of the immune system to decrease cancer progression is widely recognized and has led to the development of innovative anti-cancer immunotherapies. Here, we studied human macrophages derived from genetically engineered iPSCs (i...
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial [0.03%]
德鲁特唑胺，一种新型的雄激素受体抑制剂，在多西他赛和阿比特龙治疗后进展的转移性去势抵抗性前列腺癌中的疗效：HC-1119-04 随机3期试验结果
Junlong Wu,Xinghai Li,Chengyuan Gu et al.
Junlong Wu et al.
Metastatic castration-resistant prostate cancer (mCRPC) after treatment with docetaxel and androgen receptor signaling inhibitors (ARSIs) has limited treatment options. Although enzalutamide has shown activity after abiraterone and docetaxe...
Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy [0.03%]
快速的CAR筛选和circRNA驱动的CAR-NK细胞用于持久的抗脱落免疫治疗
Joo-Yoon Chung,Jisu Hong,Su-Min Yee et al.
Joo-Yoon Chung et al.
Chimeric antigen receptor (CAR)-based immunotherapies against solid tumors face two major hurdles, the "decoy effect" of shedding antigens that sequester CARs, and the limited persistence of immune effectors within the immunosuppressive tum...
Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond [0.03%]
靶向肿瘤微环境抗原的免疫调控疫苗：癌症研究及其以外领域的最新进展
Mads Hald Andersen
Mads Hald Andersen
Immune modulatory vaccines (IMVs) are an emerging class of immunotherapies designed to expand anti-regulatory T cells (anti-Tregs) that selectively target immunosuppressive elements within the tumor microenvironment (TME). Unlike convention...
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study [0.03%]
伊立替康联合曲氟尿苷/卡培他滨和贝伐单抗治疗二线转移性结直肠癌的Ⅱ期多中心研究
Wenwei Yang,Jing Zhang,Ping Liang et al.
Wenwei Yang et al.
Patients diagnosed with metastatic colorectal cancer (mCRC) face a constrained therapeutic landscape following the failure of initial treatment. This multicenter, single-arm, phase II trial (NCT06202001) aimed to assess the efficacy and saf...
Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer [0.03%]
糖皮质激素抵抗性的CAR-NK细胞可克服糖皮质激素引起的免疫抑制作用以治疗肺癌
Soura Chakraborty,Jhuma Pramanik,Gustavo Alviter-Raymundo et al.
Soura Chakraborty et al.
Tumors foster an immunosuppressive microenvironment to evade the antitumor immune response. However, the influence of intratumoral immunosuppressive steroids on tumor-infiltrating natural killer (NK) cells and their implications for effecti...